Mirabegron Glenmark

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adult patients.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions affecting bladder storage function within the overactive bladder disease family. - Overactive bladder: reduces the number of urgency episodes and improves bladder capacity. - Urinary urgency: helps patients gain better control over sudden urges to void. - Urinary frequency: decreases daytime voiding frequency and improves quality of life.

Adverse reactions may occur with Mirabegron therapy.

Common Side Effects: - Headache - Hypertension - Nasopharyngitis - Urinary tract infection - Constipation - Dry mouth

Serious or Rare Side Effects: - Urinary retention - Tachycardia or arrhythmia - Angioedema - Severe hypertension - Allergic skin reactions - Myocardial infarction

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: check regularly, especially after dose changes. - Assess renal function: dose adjustment may be needed in impairment. - Review cardiovascular status: use caution in patients with arrhythmias. - Evaluate concomitant medications: watch for interactions with CYP2D6 substrates. - Avoid use in uncontrolled hypertension: contraindicated in severe cases. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirabegron can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure. - Antihypertensive agents (e.g., β‑blockers): may reduce blood‑pressure‑lowering effect. - Digoxin: increased serum concentrations reported.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise Mirabegron levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy. - Diuretics: combined effect on blood pressure requires observation.